Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AFIRE Study: Atrial Fibrillation and Ischemic events with Rivaroxaban in patiEnts with stable coronary artery disease Study

Next Previous
Trial Profile

AFIRE Study: Atrial Fibrillation and Ischemic events with Rivaroxaban in patiEnts with stable coronary artery disease Study

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 12 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary) ; Aspirin; Clopidogrel; Prasugrel
  • Indications Cardiovascular disorders; Myocardial infarction; Stroke
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AFIRE Study

    • Most Recent Events

    • 29 Aug 2022 Results of post-hoc analysis assessing outcomes of rivaroxaban monotherapy (vs. combination therapy) in patients with atrial fibrillation and stable coronary artery disease across body mass index categories, presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology.
    • 13 Jun 2022 Results published in the Thrombosis and Haemostasis
    • 14 Jul 2021 Results (n= 1075) of pre-specified sub-analysis assessing efficacy and safety of P2Y12 inhibitors and aspirin in patients with stable CAD and AF, published in the Heart.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top